NCCN Drug Affordability Ratings Will Start With Multiple Myeloma, Leukemia
Executive Summary
NCCN clinical practice guidelines on multiple myeloma, chronic myeloid leukemia will be updated in October with expert ratings on cancer drug affordability, efficacy and safety. Quality, quantity and consistency of supporting data will also be rated.